Abalos Therapeutics Completes Series A Extension Bringing Total …

Oct 14, 2021 · Contacts. For more information, please contact: Abalos Therapeutics GmbH Marcus Kostka, PhD, CEO Phone: +49 211 540104-01 Email: [email protected] Abalos …

CouponFollow Extension

$38
OFF

Abalos Adds $38M In Series A Extension To Take Virotherapy Into …

1 week from now

Oct 14, 2021 · DUBLIN – Abalos Therapeutics GmbH raised €32.5 million (US$37.6 million) in a series A extension, taking the total raise to €43 million, enough to enable the company to …

bioworld.com

€32
OFF

BioCentury - Abalos Adds €32.5M To Series A Round

1 week from now

Oct 14, 2021 · Two years after launch, Abalos has expanded its series A round to a total of €43 million that will allow the German biotech to bring its arenavirus-based immunotherapy into the …

biocentury.com

€32
OFF

Abalos Therapeutics Raises €32.5M In Series A Extension - FinSMEs

1 week from now

October 15, 2021. Abalos Therapeutics, a Dusseldorf, Germany-based company harnessing arenaviruses in a differentiated immuno-virotherapy approach to fight cancer, raised €32.5M in …

finsmes.com

$50
OFF

Abalos Therapeutics Scores $50m Series A Extension

1 week from now

Oct 14, 2021 · Abalos Therapeutics scores $50m Series A extension. Abalos Therapeutics, an immuno-biotherapeutics company that targets cancer cells, has secured a $50 million …

venturecapitaljournal.com

$38
OFF

FDA’s Marks Asks VRBPAC To Consider Expanded Booster Use

1 week from now

Oct 14, 2021 · Abalos adds $38M in series A extension to take virotherapy into the clinic. DUBLIN – Abalos Therapeutics GmbH raised €32.5 million (US$37.6 million) in a series A extension, …

bioworld.com

€12
OFF

Abalos Raises €12M Series A To Develop Arenavirus-Based ... - Scrip

1 week from now

Oct 15, 2019 · Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, …

citeline.com

FAQs about Abalos Therapeutics Completes Series A Extension Bringing Total … Coupon?

How much money did Abalos Therapeutics raise?

DÜSSELDORF, Germany-- ( BUSINESS WIRE )-- Abalos Therapeutics announced today an extension to its Series A funding round bringing the total raised in this round to EUR 43 million (USD 50 million). ...

What is Abalos Therapeutics' new anti-cancer approach?

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. ...

What is Abalos Therapeutics?

About Abalos Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. ...

How does Abalos work?

Through its proprietary Fast Evolution Platform, Abalos is generating variants with optimized anti-tumoral properties to trigger a highly precise and directed immune response that can be utilized for distant metastases and enable long-term disease control. ...

What is Abalos technology?

Abalos was launched in October 2019 to advance a technology platform that harnesses the unique features of the lymphocytic choriomeningitis virus (LCMV), which specifically targets tumor cells. ...

Who will join Abalos' supervisory board?

In conjunction with the closing of the Series A financing round extension, Annegret de Baey from Seventure Partners and Sebastian Pünzeler from Coparion will join Abalos’ Supervisory Board. ...